Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

681. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial Full Text available with Trip Pro

Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial The present study assessed the efficacy and safety of vernakalant hydrochloride (RSD1235), a novel compound, for the conversion of atrial fibrillation (AF).Patients were randomized in a 2:1 ratio to receive vernakalant or placebo and were stratified by AF duration of 3 hours to 7 days (short duration) and 8 to 45 days (long duration). A first infusion of placebo or vernakalant

2008 EvidenceUpdates Controlled trial quality: predicted high

682. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy

A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy Article Text Clinical prediction guide A risk model predicted major

2008 Evidence-Based Medicine

683. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. Full Text available with Trip Pro

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. To assess the association between atrial fibrillation and flutter and use of bisphosphonates for osteoporosis among women.Population based case-control study, using medical databases from Denmark.Northern Denmark.13 586 patients with atrial fibrillation and flutter and 68 054 population controls, all with complete hospital and prescription history.Adjusted relative risk of atrial (...) , 95% confidence interval 0.85 to 1.09). The relative risk estimates were independent of number of prescriptions and the position of the atrial fibrillation and flutter diagnosis in the discharge record, and were similar for inpatients and outpatients.No evidence was found that use of bisphosphonates increases the risk of atrial fibrillation and flutter.

2008 BMJ

684. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation Full Text available with Trip Pro

Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)-related thromboembolism in a large community-based cohort.Risk schemes can help target anticoagulant therapy for patients at highest risk for AF-related thromboembolism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention (...) in Atrial Fibrillation, CHADS(2) (Congestive heart failure, Hypertension, Age >or= 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest Physicians Guidelines.We followed a cohort of 13,559 adults with AF for a median of 6.0 years. Among non-warfarin users, we identified incident thromboembolism (ischemic stroke or peripheral embolism) and risk factors from clinical databases. Each scheme was divided into low

2008 EvidenceUpdates

685. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data (Abstract)

Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data In heart failure, digitalis increases exercise capacity and reduces morbidity, but has no effect on survival. This raises the suspicion that the inotropic benefits of digitalis may be counteracted by serious adverse effects. Patients with atrial fibrillation (AF) were studied to clarify this.In the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation (SPORTIF) III and V studies

2008 EvidenceUpdates Controlled trial quality: uncertain

686. Rhythm control versus rate control for atrial fibrillation and heart failure. Full Text available with Trip Pro

Rhythm control versus rate control for atrial fibrillation and heart failure. It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately (...) studied.We conducted a multicenter, randomized trial comparing the maintenance of sinus rhythm (rhythm control) with control of the ventricular rate (rate control) in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation. The primary outcome was the time to death from cardiovascular causes.A total of 1376 patients were enrolled (682 in the rhythm-control group and 694 in the rate-control group) and were followed

2008 NEJM Controlled trial quality: predicted high

687. Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation

Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation Article Text This article has a correction. Please see: Diagnosis Accuracy of ECG interpretation in primary

2008 Evidence-Based Medicine

688. Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation

Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation Article Text Therapeutics

2008 Evidence-Based Medicine

689. Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke

Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how (...) we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients with lone atrial fibrillation had low risk of progression to permanent atrial

2008 Evidence-Based Medicine

690. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

691. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies

Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

692. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton G K, Tanajewski L, Turner D, Price A CRD summary RCTs directly comparing intravenous magnesium sulphate with sotalol were not identified, but the authors did conclude that intravenous magnesium is effective in preventing atrial fibrillation in patients undergoing coronary artery bypass graft when compared to controls. This was a well conducted piece of research, which considered limitations with the included studies. The authors' conclusions are likely to be reliable. Authors

2008 DARE.

693. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies

Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

694. Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation?

Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Murtuza B, Pepper J R, Stanbridge R D, Darzi A, Athanasiou T CRD summary The authors discovered there may be no difference in rates of postoperative atrial fibrillation after minimal (...) access aortic valve replacement compared to conventional aortic valve replacement and recommended further research. Although the conclusions appeared to be supported by the evidence, the limited literature search and lack of information about study quality mean that some caution in interpretation may be required. Authors' objectives To compare the incidence of postoperative atrial fibrillation associated with minimal access aortic valve replacement and conventional aortic valve replacement. Searching

2008 DARE.

695. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Full Text available with Trip Pro

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial (...) fibrillation Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY CRD summary The authors concluded that the optimal antithrombotic regime for atrial fibrillation in patients undergoing percutaneous coronary interventions with stenting was undefined. They recommended triple therapy (warfarin, aspirin, clopidogrel) as the most effective regime, but with an increased risk of bleeding. This recommendation may be unreliable

2008 DARE.

696. Curative ablation for atrial fibrillation: a systematic review

Curative ablation for atrial fibrillation: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

697. Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation

Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) BlueCross BlueShield Association. Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation. Chicago IL: BlueCross BlueShield Association (BCBS). TEC Assessment 23(11). 2008 Authors' objectives The objective of this Assessment is to determine whether radiofrequency catheter ablation improves health outcomes when used as a treatment for patients with atrial fibrillation. Three indications for radiofrequency catheter ablation are addressed: 1) patients with recent onset

2008 Health Technology Assessment (HTA) Database.

698. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton GK, Tanajewski L, Turner D, Price A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Southampton

2008 Health Technology Assessment (HTA) Database.

699. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. Full Text available with Trip Pro

Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. Amiodarone effectively suppresses atrial fibrillation but causes many adverse events.To compare major events in patients randomized to receive episodic amiodarone treatment with those who received continuous amiodarone treatment while still aiming to prevent atrial fibrillation.A randomized trial of 209 ambulatory patients with recurrent symptomatic persistent atrial (...) fibrillation, conducted from December 2002 through March 2007 at 7 Dutch medical centers.Patients were randomly assigned to receive either episodic or continuous amiodarone treatment after electrical cardioversion following amiodarone loading. Episodic amiodarone treatment was discontinued after a month of sinus rhythm and reinitiated if atrial fibrillation relapsed (1 month peri-electrical cardioversion). In the continuous treatment group amiodarone was maintained throughout.The primary end point

2008 JAMA Controlled trial quality: predicted high

700. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. Full Text available with Trip Pro

Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. Pulmonary-vein isolation is increasingly being used to treat atrial fibrillation in patients with heart failure.In this prospective, multicenter clinical trial, we randomly assigned patients with symptomatic, drug-resistant atrial fibrillation, an ejection fraction of 40% or less, and New York Heart Association class II or III heart failure to undergo either pulmonary-vein isolation or atrioventricular-node (...) % of patients receiving antiarrhythmic drugs and 71% of those not receiving such drugs were free of atrial fibrillation at 6 months. In the group that underwent pulmonary-vein isolation, pulmonary-vein stenosis developed in two patients, pericardial effusion in one, and pulmonary edema in another; in the group that underwent atrioventricular-node ablation with biventricular pacing, lead dislodgment was found in one patient and pneumothorax in another.Pulmonary-vein isolation was superior to atrioventricular

2008 NEJM Controlled trial quality: uncertain